Market revenue in 2023 | USD 27.6 million |
Market revenue in 2030 | USD 61.2 million |
Growth rate | 12% (CAGR from 2023 to 2030) |
Largest segment | Immunotherapy |
Fastest growing segment | Immunotherapy |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Chemotherapy, Immunotherapy, Targeted Therapy |
Key market players worldwide | Eli Lilly and Co, Sanofi SA, Merck & Co Inc, Bristol-Myers Squibb Co, AstraZeneca PLC, Takeda Pharmaceutical Co Ltd, Teva Pharmaceutical Industries Ltd, Roche Holding AG ADR, Clinigen Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to head and neck cancer therapeutics market will help companies and investors design strategic landscapes.
Immunotherapy was the largest segment with a revenue share of 60.14% in 2023. Horizon Databook has segmented the Sweden head and neck cancer therapeutics market based on chemotherapy, immunotherapy, targeted therapy covering the revenue growth of each sub-segment from 2018 to 2030.
The pharmaceutical market in Sweden is highly regulated and characterized by a strong emphasis on patient safety and access to innovative medicines. The country has a universal healthcare system, which means that the government plays a significant role in the pricing and reimbursement of pharmaceutical products.
The Swedish Medical Products Agency (MPA) regulates and approves medicines, ensuring their safety, efficacy, & quality. In Sweden, there is a high prevalence of head and neck cancer, which creates a significant demand for therapeutics in the country.
In September 2023, Beactica Therapeutics AB, a Sweden-based company, collaborated with the National Center for Advancing Translational Sciences (NCATS) related to research on cancer. This collaboration can help enhance the potential of the company’s proprietary targeted degraders of TEAD for research in cancer treatment, including head and neck cancer.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden head and neck cancer therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Sweden head and neck cancer therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account